Current and future drug treatment for posttraumatic stress disorder patients

Psychiatric Annals

Volumn 28, Issue 8, 1998, Pages 461-468

  Friedman, Matthew J ^a,b  

^a NATIONAL CENTER FOR PTSD   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0032334820     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-19980801-10     Document Type: Article

References (38)

1. van der Kolk BA, Dryfuss D, Michaels M, et al. Fluoxetine in post-traumatic stress disorder. J Clin Psychiatry. 1994;55:517-522.
2. Friedman MJ. Biological alterations in PTSD: implications for pharmacotherapy. In: Giller E, Weisaeth L, eds. Bailliere's Clinical Psychiatry: International Practice and Research: Post-Traumatic Stress Disorder. London: Bailliere Tindall; 1996;2:245-262.
3. Rothbaum BO, Ninan PT, Thomas L. Sertraline in the treatment of rape victims with posttraumatic stress disorder. J Traumatic Stress. 1996;9:865-871.
4. Marmar CR, Schoenfeld F, Weiss DS, et al. Open trial of fluvoxamine treatment for combat-related posttraumatic stress disorder. J Clin Psychiatry. 1996;57(suppl 8):66-72.
5. Davidson JRT, Malik ML, Sutherland SN. Response characteristics to antidepressants and placebo in post-traumatic stress disorder. Int Clin Psychopharmacol. 1997;12:291-296.
6. Brady KT, Sonne SC, Roberts JM. Sertraline treatment of comorbid posttraumatic stress disorder and alcohol dependence. J Clin Psychiatry. 1995;56:502-505.
7. Friedman MJ. Interrelationships between biological mechanisms and pharmacotherapy of post-traumatic stress disorder. In: Wolfe ME, Mosnaim AD, eds. Post-Traumatic Stress Disorder: Etiology, Phenomenology, and Treatment. Washington, DC: American Psychiatric Press; 1990:204-225.
8. Hertzberg MA, Feldman ME, Beckham JC, et al. Trial of trazadone for post-traumatic stress using a multiple baseline group design. J Clin Psychopharmacol. 1996;16:294-298.
9. Cook MD, Conner J. Retrospective review of hypnotic use in combination with fiuoxetine or sertraline. Clin Drug Invest. 1995;9:212-216.
10. Wells GB, Chu C, Johnson R, et al. Buspirone in the treatment of post-traumatic stress disorder. J Clin Psychiatry. 1991;55:517-522.
11. Friedman MJ, Charney DS, Deutch AY. Neurobiologlcal and Clinical Consequences of Stress: From Normal Adaptation to PTSD. Philadelphia, PA: Lippincott-Raven; 1995.
12. Yehuda R, McFarlane AC. Psychobiology of posttraumatic stress disorder. Ann NY Acad Sci. 1997;821.
13. Kolb LC, Burris BC, Griffiths S. Propranolol and clonidine in the treatment of the chronic post-traumatic stress disorders of war. In: van der Kolk BA, ed. Post-Traumatic Stress Disorder: Psychological and Biological Sequelae. Washington, DC: American Psychiatric Press; 1984: 97-107.
14. Famularo R, Kinscherff R, Fenton T. Propranolol treatment for childhood post-traumatic stress disorder, acute type: a pilot study. Am J Dis Child. 1988;142:1244-1247.
15. Friedman MJ, Southwick SM. Towards pharmacotherapy for PTSD. In: Friedman MJ, Charney DS, Deutch AY, eds. Neurobiological and Clinical Consequences of Stress: From Normal Adaptation to PTSD. Philadelphia, PA: Lippincott-Raven; 1995:465-481.
16. Hannon RJ, Riggs PD. Clonidine for posttraumatic stress disorder in preschool children. J Am Acad Child Adolesc Psychiatry. 1996;35:1247-1249.
17. Horrigan JP. Guanfacine for PTSD nightmares (Letter). J Am Acad Child Adolesc Psychiatry. 1996;35:975-976.
18. Korrigan JP, Barnhill LJ. The suppression of nightmares with guanfacine (Letter). J Clin Psychiatry. 1996;57:371.
19. Kosten TR, Frank JB, Dan E, et al. Pharmacotherapy for post-traumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis. 1991;179 366-370.
20. Shestatzky M, Greenberg D, Lerer B. A controlled trial of phenelzine in post-traumatic stress disorder. Psychiatr Res. 1988;24:149-155.
21. DeMartino R, Mollica RF, Wilk V. Monoamine oxidase inhibitors in post-traumatic stress disorder. J Nero Ment Dis. 1995;183 510-515.
22. Weizman R, Laor N, Schujovitsky A, et al. Platelet imipramine binding in patients. Psychiatr Res. 1996;63:143-150.
23. Southwick SM, Yehuda R, Giller EL, et al. Use of tricyclics and monoamine oxidase inhibitors in the treatment of PTSD: a quantitative review. In: Murburg MM, ed. Catecholamine Function in Post-traumatic Stress Disorder: Emerging Concepts. Washington, DC: American Psychiatry Press; 1994:293-305.
24. Neal LA, Shapland W, Fox C. An open trial of moclobemide in the treatment of post-traumatic stress disorder. Int Clin Psychopharmacol. 1997;12:231-237.
25. Baker DG, Diamond BI, Gillette G, et al. A double-blind, randomized placebo-controlled multi-center study of brofaromine in the treatment of post-traumatic stress disorder. Psychopharmacology. 1995;122:386-389.
26. Katz RJ, Lott MH, Arbus P, et al. Pharmacotherapy of post-traumatic stress disorder with a novel psychotropic. Anxiety. 1995;1:169-174.
27. Ver Ellen P, van Kammen DP. The biological findings in post-traumatic stress disorder: a review. J Appl Soc Psychol. 1990;20:1789-1821.
28. Davidson J, Kudler H, Smith R, et al. Treatment of post-traumatic stress disorder with amitriptyline and placebo. Arch Gen Psychiatry. 1990;47:259-266.
29. Reist C, Kauffman CD, Haier RJ, et al. A controlled trial of desipramine in 18 men with post-traumatic stress disorder. Am J Psychiatry. 1989;146:513-516.
30. Braun P, Greenberg D, Dasberg H, et al. Core symptoms of post-traumatic stress disorder unimproved by alprazolam treatment. J Clin Psychiatry. 1990;51:236-238.
31. Gelpin E, Bonne O, Peri T, et al. Treatment of recent trauma survivors with benzodiazepines: a prospective study. J Clin Psychiatry. 1996;57:390-394.
32. Post RM, Weiss SRB, Smith MA. Sensitization and kindling: implications for the evolving neural substrate of PTSD. In: Friedman MJ, Charney DS, Deutch AY, eds. Neurobiological and Clinical Consequences of Stress: From Normal Adaptation to PTSD. Philadelphia, PA: Lippincott-Raven; 1995:203-224.
33. Clover H. A preliminary trial of nalmefane for the treatment of emotional numbing in combat veterans with post-traumatic stress disorder. Israel J Psychiatry Related Sci. 1993;30:255-263.
34. McGee MD. Cessation of self-mutilation in a patient with borderline personality disorder treated with naltrexone (Letter). J Clin Psychiatry. 1997;58:32-33.
35. Dillard ML, Bendfeldt F, Jernigan P. Use of thioridazine in post-traumatic stress disorder. South Med J. 1993;86:1276-1278.
36. Hamner MB. Clozapine treatment for a veteran with comorbid psychosis and PTSD (Letter). Am J Psychiatry. 1996;153:841.
37. Krystal JH, Bennett A, Bremner ID, et al. Toward a cognitive neuroscience of dissociation and altered memory functions in post-traumatic stress disorder. In: Friedman AS, Charney DS, Deutch AY, eds. Neurobiological and Clinical Consequences of Stress: From Normal Adaptation to PTSD. Philadelphia, PA: Lippincott-Raven; 1995:239-270.
38. Rasmusson AM, Charney DS. Animal models of relevance to PTSD. Ann NY Acad Sci. 1987;821:332-351.